KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
January 25 2019 - 10:00AM
InvestorsHub NewsWire
Dallas, TX --
January 25, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced an online corporate update
scheduled for Wednesday next week on January 30, 2019. The
presentation will include updates on KALY’s developments with
Puration, Inc, (USOTC:
PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB:
GNBT). The presentation will also include updates on the
company’s Hemp4mula product developments. The highlight of
the presentation will feature the latest on the company’s research
on treatments for Chronic Obstructive Pulmonary
Disease (COPD). KALY has completed an in vitro genomics
study to evaluate the impact of its pharmaceutical grade cannabis
extracts in combination with other therapies on COPD patients.
Favorable results prompted the launch of a physiological study
whose results will be released later this quarter. The World Health
Organization estimates 65 million people worldwide are afflicted
with moderate to severe COPD and GlobalData forecasts that the COPD
treatment market will reach $14.1 billion by
2025.
Goldman Small
Cap Research Report published an analyst research report on KALY on
January 8th, 2019 that highlights KALY’s cannabis
pharmaceutical value. The report is available under
“research” on the OTCMarkets website. The research
report is the first report from Goldman Small Cap Research as part
of an ongoing research engagement. The report outlines the
company’s current positioning and potential, upcoming milestones.
The report is intended to augment the current information available
on the OTCMarkets website. The report is also available to read or
download, along with associated disclosures and disclaimers,
at www.GoldmanResearch.com.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2024 to Jun 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jun 2023 to Jun 2024